10 studies found for:    vedolizumab
Show Display Options
Rank Status Study
1 Not yet recruiting Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Vedolizumab;   Drug: Vedolizumab placebo
2 Not yet recruiting Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Vedolizumab;   Drug: Vedolizumab placebo
3 Completed Long Term Safety of MLN0002 in Patients With Ulcerative Colitis and Crohn's Disease
Conditions: Ulcerative Colitis;   Crohn's Disease
Intervention: Drug: vedolizumab (MLN0002)
4 Completed Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: vedolizumab;   Other: Placebo
5 Completed Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
Condition: Inflammatory Bowel Disease
Interventions: Drug: Vedolizumab;   Drug: Placebo
6 Active, not recruiting An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
Conditions: Ulcerative Colitis;   Crohn's Disease
Intervention: Drug: vedolizumab
7 Completed Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: vedolizumab;   Other: Placebo
8 Completed Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: vedolizumab;   Other: Placebo
9 Completed Study of MLN0002 Following Multiple Intravenous Doses in Patients With Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: vedolizumab (MLN0002);   Drug: Placebo
10 Completed Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients
Condition: Crohn's Disease
Interventions: Drug: LDP-02;   Drug: Placebo

Indicates status has not been verified in more than two years